Farmacon Global

Building a Federated Future for Ethical Clinical Research

Farmacon Global is developing a network of federated data nodes across Latin America to support ethical, transparent, and regionally controlled clinical research.

Today, most medical data in the region is exported to centralized sponsor platforms. This creates dependency and prevents local institutions from building long-term value. Our goal is to change that — by ensuring that Latin American hospitals, universities, and software teams are the ones hosting, protecting, and profiting from their own data.

“This initiative builds on Farmacon Global’s long-standing work in clinical research oversight and ethics across Latin America.”

What “Data Sovereignty” Means

Data sovereignty is the right to control, access, and benefit from your own data.
Our model ensures that:

  • Data stays within national legal and physical borders.

  • Local institutions hold the encryption keys.

  • Only aggregated insights — never raw data — are shared externally.

This approach strengthens compliance, transparency, and trust between patients, physicians, and sponsors.

The Federated Network Model

Our partners host secure, local data nodes that connect through a shared protocol layer.
Each node:

  1. Keeps patient data safely on-site.

  2. Participates in analysis through federated learning.

  3. Shares only encrypted, aggregated results.

This allows research collaboration without data extraction — and builds the foundation for a sovereign biotech economy in Latin America.

Bitfount logo

Bitfount has officially joined as our technology partner for initial implementation.
We are now seeking additional local partners to expand this network across the region.

Join the Network

We are currently identifying

✽ Data-science teams

✽ Software companies

✽ Research institutions

✽ Technical nonprofits

that can host or support local data nodes in Latin America.

If your organization values privacy, ethics, and regional capacity-building, we would love to collaborate.

Rare DIEM Logo

Contact: tatiana@farmasc.com

Sara Tylosky, MBA
CEO

Sara Tylosky, MBA, CEO at Farmacon Global, brings over 20 years of experience leading teams in both large and small pharmaceutical and biotech environments. She has led Farmacon Global, a strategic CRO of medical consultants, in accelerating clinical trials, increasing diversity, supporting enrollment, and paving the way to market access in emerging markets.

Known for her high cultural intelligence and problem-solving skills, Sara and her team specialize in Rare Diseases, Immunology, Infectious Diseases, Cancer, and Vaccines. Fluent in Spanish and having lived on four continents, she has a special focus on Latin America while actively expanding into other key markets globally. Sara’s direction plays a pivotal role in steering Farmacon Global toward healthcare innovation and global market leadership.